WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS: Cytopenias : Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia[see WARNINGS AND PRECAUTIONS (5.1)]. Infusion Reactions : Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days[see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)]. Infections : Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
diseasome-diseases:1173, diseasome-diseases:1693, diseasome-diseases:1694, diseasome-diseases:181, diseasome-diseases:2789, diseasome-diseases:3004, diseasome-diseases:3020, diseasome-diseases:3365, diseasome-diseases:4136, diseasome-diseases:602, diseasome-diseases:698, diseasome-diseases:701, diseasome-diseases:833